ACRIA Update
Spring 2006 - Vol.15 No. 2
New Drugs from Old Classes
A number of new drugs from existing classes are being studied. Here's a brief rundown of drugs that have started trials in people:
Nucleoside Analog Reverse Transcriptase Inhibitors (NRTIs):
Amdoxovir (DAPD): Early results from an ongoing Phase II study (in people resistant to other NRTIs) showed only a modest anti-HIV effect after two weeks on the drug.
AVX 754: active in vitro against HIV resistant to other NRTIs. Currently in early Phase II trials.
Racivir (PSI 5004): similar to Emtriva (FTC); active against HIV and hepatitis B virus that is resistant to Epivir (3TC). Currently in Phase II trials.
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs):
Etravirine (TMC 125): Recent study showed effectiveness in people resistant to Sustiva and Viramune; may be very strong in people who have never taken an NNRTI. Currently in Phase II trials. Taken twice a day.
TMC278 (DAPY): shows in vitro activity against NNRTI-resistant virus; in early development.
Protease Inhibitors (PIs):
Brecanavir (GW 640385): active in vitro against resistant virus. In Phase II trials. Taken with Norvir.
Darunavir (TMC 114): Phase II trial showed drug to be effective in people with multi-drug resistance - may receive FDA approval as early as this summer. Taken twice daily with Norvir (ritonavir).
|
